Abstract
Introduction & Objectives: There are a range of mechanisms and systems underlying urinary bladder contractions, with interactions between nerves, endogenously released chemicals and receptors all playing a part in the overall function1,2. However, when contraction is inhibited, such as with underactive bladder, it can be challenging to work out which mechanisms may be at fault. Nonetheless, it is feasible that parasympathomimetics (muscarinic agonists and acetylcholinesterase inhibitors) might be beneficial for enhancing contractions of the urinary bladder, which is of particular interest in the pharmaceutical treatment of underactive bladder. This study systematically reviewed and meta-analysed the current literature to assess the effectiveness of muscarinic agonists and
acetylcholinesterase inhibitors for the treatment of underactive bladder.
acetylcholinesterase inhibitors for the treatment of underactive bladder.
| Original language | English |
|---|---|
| Pages (from-to) | 35-35 |
| Number of pages | 1 |
| Journal | Australian and New Zealand Continence Journal |
| Volume | 29 |
| Issue number | 2 |
| Publication status | Published - 16 Jun 2023 |
| Event | Joint 31st National Conference on Incontinence (NCOI) and the 4th Functional Urology Symposium (FUS) (NCOIFUS23) - Adelaide Convention Centre, Adelaide, Australia Duration: 14 Jun 2023 → 17 Jun 2023 Conference number: 30 https://www.continence.org.au/NCOI |